Chronic inflammatory diseases – manufacturing of a specific drug
The invention on hand deals with a drug against chronic inflammatory diseases which is specific for a cell or tissue type, a particular disease or a particular disease stage. Proteins and nucleic acids that are specific for a disease, a cell type, a tissue or a disease stage are identified with regard to their changed expression pattern. The respective nucleic acids are analyzed in consideration of their suitability as targets for DNAzymes oder siRNA. Active specific DNAzymes and siRNA are designed thereupon, binding to target sequences and cleaving them. In doing so, the current invention provides a drug against chronic inflammatory and autoimmune diseases.
The drug preferentially affects the points of intervention of the complex cascade of immunologic and cytologic misregulations underlying chronic inflammation and autoimmune reactions. The regulation of the differentiation of the transcription factors involved in the cascade, as e.g. the TH2 cell specific transcription factor GATA-3 or the TH1 cell specific transcription factor T-bet, is indicative of such a point of intervention.
Further Information: PDF
TransMIT Gesellschaft für Technologietransfer mbH
Phone: +49 (0)641/943 64-12
Dr. Peter Stumpf
Alle Nachrichten aus der Kategorie: Technology Offerings
Scientists achieve higher precision weak force measurement between protons, neutrons
Through a one-of-a-kind experiment at the Department of Energy’s Oak Ridge National Laboratory, nuclear physicists have precisely measured the weak interaction between protons and neutrons. The result quantifies the weak…
High-performance single-atom catalysts for high-temperature fuel cells
Individual Pt atoms participate in catalytic reaction to faciitate the electrode process by up to 10 times. Single-atom Pt catalysts are stable at 700 degrees Celsius and expected to stimulate…